TrialFrontiers in immunology2022
Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome.
Fabrizio Pane et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papercites it